Historical Developments in drug Protection from the Pre-Modern to the Post-Modern Era: A Legal Approach to drug Counterfeiting
Tārīkh-i pizishkī i.e., Medical History,
Vol. 16 (1403),
7 May 2024
,
Page 1-23
https://doi.org/10.22037/mhj.v16i.45546
Abstract
Background and Aim: Examining the evolution of drug protection practices from the pre-modern to the post-modern era, dating back to 3000 BC, is essential to gain a comprehensive understanding of trends, historical patterns and evidence-based strategies for addressing the problem of counterfeit drugs in the modern era. Tracing this evolutionary path provides valuable insights into the historical context, challenges and advances made in combating the illicit production and distribution of counterfeit drugs. This paper traces the historical trajectory of efforts to protect pharmaceutical products against counterfeiting over time and outlines key historical developments, innovations and regulatory frameworks that have shaped the landscape of drug safety and anti-counterfeiting efforts.
Methods: This research, using an analytical-descriptive and quantitative coursework method, based on reliable documentation and archival sources, including domestic and foreign books and articles, has examined the status of the protection of pharmaceutical products and how its laws and regulations have evolved over the period from 3000 BC to 2024 by searching for the keywords laws, drug protection, public health, counterfeiting, ancient, modern and postmodern in the electronic scientific database Google Scholar.
Ethical Considerations: In this study, ethical considerations, honesty and trustworthiness have been observed in referencing texts to the sources.
Results: The evolution of legal measures to protect pharmaceutical products shows the transition from primitive customary laws to formal frameworks in the modern era. The introduction of pharmacopoeias and consumer protection laws marked significant advances in regulating the drug quality and authenticity. Legal and ethical approaches to protect pharmaceutical products have evolved significantly from the pre-modern to the post-modern era, accompanied by technological advances.
Conclusion: Inspired by historical developments and adapting to new challenges, it emphasizes the need for continued vigilance and the development of innovation and new technologies in protecting public health and ensuring the safety and efficacy of pharmaceutical products. It is essential to shift regulatory strategies related to regulatory practices from a reactive approach to a proactive and practical stance focused on prevention.
- Historical Developments
- Counterfeit Medicine
- Pre-Modern
- Medicine
- Protection
- Post-Modern
How to Cite
References
Mohammadi M, Jalali S, Tavakkoli Z, Ghahremani nejad F. Medicinal plants of Bazarjan region (Tafresh, Markazi Province, Iran). Applied Biology. 2020; 33(3): 122-34. [Fulltext in Persian]
Barrantes JB, Quesada MS, Rojas G, Loria A. A journey through the history of drug quality control, from Greece to Costa Rica. International Journal of Drug Regulatory Affairs. 2021; 9(1): 33-47.
Jamshidi-Kia F, Lorigooini Z, Amini-Khoei H. Medicinal plants: Past history and future perspective. Journal of Herbmed Pharmacology. 2017; 7(1): 1-7.
Ferner RE, Aronson JK. Medicines legislation and regulation in the United Kingdom 1500‐2020. British Journal of Clinical Pharmacology. 2023; 89(1): 80-92.
WHO. Definitions of substandard and Falsified (SF) medical products. Geneva: WHO Publications; Available at: https://www.who.int/medicines/regulat ion/ssffc/definitions/en/. Accessed April 9, 2017.
Tseng JH, Liao YC, Chong B, Liao SW. Governance on the drug supply chain via gcoin blockchain. International Journal of Environmental Research and Public Health. 2018; 15(6): 1055.
Niavarani S, Javid E. The right of access to essential medicines under the TRIPS Agreement and the challenge of upholding international human rights to health. International Journal of Law. 2015; 4(54): 27-29. [Persian]
Ghanbari MA, Delpasand K, Ghanbari A. Inclusion of Traditional and Complementary Medicine in the United Nations Strategy and the World Health Organization. Tārīkh-I Pizishkī. 2020; 11(41): 7-22. [Persian]
Ghezelsofla MT. Epistemological characteristics of thought in pre-modern, modern and postmodern times. Political Science Research Journal. 2007; 3(1): 119-157. [Persian]
Harris B, Zucker S. A Brief History of Western Culture. Arts and humanities. College Art History, Khan Academy. 2024. p.2. Available at: https://www.khanacademy.org/humanities/ap-art-histor y/start-here-apah/brief-histories-apah/a/a-brief-history-of-western-culture.
Danaei G, Farzadfar F, Kelishadi R, Rashidian A, Rouhani OM, Ahmadnia S, et al. Iran in transition. The Lancet. 2019; 393(10184): 1984-2005.
Pourahmad J. History of medical sciences in Iran. Iranian Journal of Pharmaceutical Research. 2008; 7(2): 93-99.
Mohajer Rahbari M, Rajab Nejad M, Ghabili K, Torbati M, Khalili M. History and luminaries of medical education in Iran. JLS. 2014; 4: 1600-1608.
Farsam H. Brief History of pharmacy ethics in Iran. Journal of Medical Ethics and History of Medicine. 2009; 2: 1-4.
Siraj Al-Dini MF. Herbal therapy and medicine in ancient Iran. Journal of Medical History-Shahid Beheshti University of Medical Sciences. 2016; 2(2): 11-33. [Persian]
Kaviani Pouya H. Medicine and the evolution of treatment in ancient Iran. Journal of Medical History. Shahid Beheshti University of Medical Sciences. 2010; 2(3): 67-98. [Fulltext in Persian]
Moattar F, Moattar H, Moattar H. The art of medicine and pharmacology in ancient Iran. Traditional Medicine of Islam and Iran. 2010; 1(4): 373-377. [Fulltext in Persian]
Hosseini Kazerouni SA. Background of medical knowledge and intellectual sciences in Iran (according to Persian and Arabic literary texts). Educational and Lyrical Research of Persian Language and Literature. 2010; 3(6): 83-103. [Persian]
Wee JZ. Ghosts In and Outside the Machine: A Phenomenology of Intelligence, Psychic Possession and Prophetic Ecstasy in Ancient Mesopotamia. 1st ed. The Routledge Companion to Ecstatic Experience in the Ancient World. No Place: Routledge; 2021. p.397-429.
Pittman H. Seals and sealing in the Sumerian world. The Sumerian World. 1st ed. No Place: Routledge; 2013. p.319-341.
Pearn J. Hammurabi’s Code: A primary datum in the conjoined professions of medicine and law. Medico-Legal Journal. 2016; 84(3): 125-131.
Pouyan N. Mesopotamia, the cradle of civilization and medicine. World Journal of Pharmaceutical Research. 2016; 5(4): 192-225.
Halwani T, Takrouri M. Medical laws and ethics of Babylon as read in Hammurabi’s code (History). The Internet Journal of Law, Healthcare and Ethics. 2006; 4(2): 1-8.
Sukacic M. Consumer protection in ancient Rome-lex iulia de annona and edictum de pretiis rerum venalium as prohibitions of abuse of dominant position? Economic and Social Development: Book of Proceedings. 22nd International Scientific Conference on Economic and Social Development "Legal Challenges of Modern World"; 2017. p.107-117.
Pasipoularides A. Galen, father of systematic medicine. An essay on the evolution of modern medicine and cardiology. International Journal of Cardiology. 2014; 172(1): 47-58.
Veiga P. Health and Medicine in ancient Egypt; magic and science. Doctoral Dissertation. Lisbon: Universidade de Lisboa; 2009.
Dare T. Ancient Egyptian Medicine Chapter 3: The Ancient World (before 500 BCE)-Farmers to Pharaohs. "History of Applied Science & Technology: An Open Access Textbook". 2017. p.22. Available at: https://commons.und.edu/oers/22.
Higby GJ. American hospital pharmacy from the Colonial period to the 1930s. American Journal of Health-System Pharmacy. 1994; 51(22): 2817-2823.
Chen S, Chen Q, Askool YS, Xu L. Textual Research on Dioscorides and De Materia Medica. Chinese Medicine. 2023; 14(3): 208-219.
Klerk S. Teaching materia medica at Leiden University: Between natural history, botany and the foundations of medicine (1587-1617). Edited by van Gelder E, Robin N. Yearbook for European Culture of Science. 2011; 1(6): 1-23.
Solomon RC. Corporate roles, personal virtues: An Aristotelean approach to business ethics. Business Ethics Quarterly. 1992; 2(3): 317-339.
Dehghani Mahmoodabadi MH. Happiness in the hedonistic schools (criticism of the moral schools of Socrates, Plato, Aristotle). Journal of Marafet. 2008; 128(5): 139-157. [Fulltext in Persian]
Bhatt V, Ogaki M, Yaguchi Y. Normative behavioral economics based on unconditional love and moral virtue. The Japanese Economic Review. 2015; 66: 226-246.
Liu CX, Xiao PG, Song NN. Traditional Chinese medicines: The challenge of acceptance by Western medicine. Evaluation of Herbal Medicinal Products. Edited by Houghton P, Mukherjee PK. London: Pharmaceutical Press; 2009.
Zhao Z, Guo P, Brand E. A concise classification of bencao (materia medica). Chinese Medicine. 2018; 13: 1-4.
Bush JF. By Hercules! The More Common the Wine, the More Wholesome! Science and the Adulteration of Food and Other Natural Products in Ancient Rome. Food and Drug Law Journal. 2002; 57(3): 573-602.
Mousavi J, Badkobeh Hezaveh A, Ghafari F, Shariat Panahi SM. The history of leaf organ morphology in Islamic Iranian botany (from the 3rd to the 5th century AH). History of Medicine. 2012; 5(15): 139-175. [Persian]
Parvin Rou SH, Ghafari F. The scientific-ethical approach of Minhaj al-Dakan's book in pharmaceuticals. Journal of Medical Ethics-Scientific Research. 2009; 3(8): 127-146. [Fulltext in Persian]
Mohammadi F, Kasiri M, Rahimi R. Investigating the books of material medicas from al-Hashaish (3 AH) to the Mohit Azam (13 AH) relying on index books in the areas ruled by Islam. Journal of Islamic and Iranian Traditional Medicine. 2019; 10(3): 269-290.
Hemmati M, Fazlinejad A. A Study of Iranians’ Innovations in Pharmacology from Jondi Shapur to Shiraz School. Journal of Research on History of Medicine. 2018; 7(3): 127-148.
Mojab F. Pharmacology and pharmacy in Ibn Sina's law book. Medicine and Cultivation. 2008; 16(1-2): 36-43. [Persian]
Mann RD. From mithridatium to modern medicine: The management of drug safety. Journal of the Royal Society of Medicine. 1988; 81(12): 725-728.
Farsam H. Pathology of pharmaceutical ethics. Iranian Journal of Medical Ethics and History. 2007; 1(1): 61-66. [Persian]
Bolt N. Mediaeval Quality Assurance of Medicines within the Territory of the State of Burgundy. Journal of Pharmacy and Pharmacology. 2020; 8: 228-239.
Bolt N. Monopoly, competition and regulation: Medieval apothecaries in the State of Burgundy, 1300-1600. Pharmaceutical Historian. 2021; 51(1): 1-5.
Burnby J. A Study of the English Apothecary from 1660 to 1760. London: University of London; 1979.
Medeiros MFT, de Albuquerque UP. The pharmacy of the Benedictine monks: The use of medicinal plants in Northeast Brazil during the nineteenth century (1823-1829). Journal of Ethnopharmacology. 2012; 139(1): 280-286.
Akbari M, Mohammadnabi S. The role of the crusades in the transfer of Iranian Islamic medicine to Europe. Iran's Ethics and History of Medicine. 2021; 14: 216-228. [Persian]
Žuškin E, Lipozenčić J, Pucarin-Cvetković J, Mustajbegović J, Schachter N, Mučić-Pučić B, et al. Ancient medicine-a review. Acta Dermatovenerologica Croatica. 2008; 16(3): 149-157.
Anderson S. Pharmacy in the Medieval World, 1100-1617 AD.Chapter 3 of book: Making Medicines: A Brief History of Pharmacy and Pharmaceuticals. ISBN9780857110992; 2005. Page count:336 p.37-56.
Gentilcore D. For the Protection of Those Who Have Both Shop and Home in this City: Relations between Italian Charlatans and Apothecaries. Pharmacy in History. 2003; 45(3): 22-108.
Moote AL. The French Crown versus its judicial and financial officials, 1615-83. The Journal of Modern History. 1962; 34(2): 146-160.
Moghbel AH. The evolution of medicine and pharmaceuticals in the world 1- From Mesopotamia to Jundi Shapur. Jundishapur Scientific Medical Journal. 2013; 12(5): 453-465. [Persian]
Food Safety Regulatory Issues (SAFE 408/608). History of US Food Law (sec 1). Milestones in US Food and Drug Law History. 2023. Available at: https://www.fda.gov/about-fda/fda-history/milestones-us-food-and-drug-law.
Griffenhagen GB. Great Moments in Pharmacy: Development of the Robert Thorn Series Depicting Pharmacy's History. Journal of the American Pharmaceutical Association. 2002; 42(2): 170-182.
Drugs C. Guidelines for the development of measures to combat counterfeit drugs. Geneva: WHO; 1999:1-60.
Mackey TK, Liang BA. Improving global health governance to combat counterfeit medicines: A proposal for a UNODC-WHO-Interpol trilateral mechanism. BMC Medicine. 2013; 11: 1-10.
Organization WH. Definitions of substandard and Falsified (SF) medical products. Geneva: World Health Organization; 2017.
Lima MBA, Yonamine M. Counterfeit medicines: Relevance, consequences and strategies to combat the global crisis. Brazilian Journal of Pharmaceutical Sciences. 2023; 59: e20402.
Karev N, Raychev D. Serialization of Pharmaceutical Products: EU Delegated ACT 2016/161 to protect against counterfeit medicines. Journal of Chemical Technology and Metallurgy. 2019; 54(6): 1-6.
Hall A, Koenraadt R, Antonopoulos GA. Illicit pharmaceutical networks in Europe: Organizing the illicit medicine market in the United Kingdom and the Netherlands. Trends in Organized Crime. 2017; 20(3): 296-315.
- Abstract Viewed: 218 times
- pdf (فارسی) Downloaded: 142 times